LONDON (Alliance News) - Midatech Pharma PLC on Monday announced the full commercial launch in the US of Zuplenz, an oral soluble film to prevent post-operative, chemotherapy and radiation-induced nausea and vomiting.
"Zuplenz is a valuable treatment option that offers convenient relief from one of the most debilitating side-effects of common cancer treatments. The product launch of Zuplenz represents yet another step forward for Midatech and further leverages our commercial infrastructure in the US. Zuplenz is a perfect example of our rapidly growing portfolio of marketed oncology products and will further contribute to our growing revenue stream," Chief Executive Officer Jim Phillips said in a statement.
Shares in Midatech were up 10% at 178.00 pence on Monday afternoon.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.
